Bisphosphonate risks and benefits: Finding a balance

Journal of Clinical Oncology

Volumn 28, Issue 33, 2010, Pages 4873-4876

  Gralow, Julie R ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PAMIDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER PATIENT; DRUG TOLERABILITY; EDITORIAL; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCALCEMIA; MULTIPLE MYELOMA; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SOLID TUMOR; STROKE; SUPRAVENTRICULAR TACHYCARDIA;

ATRIAL FIBRILLATION; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; SEER PROGRAM; STROKE;

EID: 79951925512     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.1464     Document Type: Editorial

References (38)

1. Coleman RE, Winter MC, Cameron D, et al: The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: Exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 102:1099-1105, 2010
2. Lipton A: Emerging role of bisphosphonates in the clinic: Antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 34:S25-S30, 2008 (34 suppl 1)
3. Fournier PG, Stresing V, Ebetino FH, et al: How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia 12:571-578, 2010
4. Diel IJ, Jaschke A, Solomayer EF, et al: Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: A long-term follow-up. Ann Oncol 19:2007-2011, 2008
5. Powles T, Paterson A, McCloskey E, et al: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 8:R13, 2006
6. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
7. Newcomb PA, Trentham-Dietz A, Hampton JM: Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 102:799-802, 2010
8. Chlebowski RT, Chen Z, Cauley JA, et al: Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28:3582-3590, 2010
9. Rennert G, Pinchev M, Rennert HS: Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28:3577-3581, 2010
10. Fraunfelder FW, Fraunfelder FT: Bisphosphonates and ocular inflammation. N Engl J Med 348:1187-1188, 2003
11. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al: Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62:527-534, 2004 (Pubitemid 38542516)
12. Migliorati CA: Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21:4253-4254, 2003
13. FDA: Information for healthcare professionals: Bisphosphonates. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm124165.htm
14. Goh SK, Yang KY, Koh JS, et al: Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J Bone Joint Surg Br 89:349-353, 2007 (Pubitemid 46563912)
15. Lenart BA, Lorich DG, Lane JM: Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304-1306, 2008 (Pubitemid 351439247)
16. Abrahamsen B, Eiken P, Eastell R: Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: A register-based national cohort study. J Bone Miner Res 24:1095-1102, 2009
17. Black DM, Delmas PD, Eastell R, et al: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822, 2007
18. Cummings SR, Schwartz AV, Black DM: Alendronate and atrial fibrillation. N Engl J Med 356:1895-1896, 2007
19. Lyles KW, Colón-Emeric CS, Magaziner JS, et al: Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809, 2007 (Pubitemid 350044800)
20. FDA: Update of safety review follow-up to the October 1, 2007, early communication about the ongoing safety review of bisphosphonates. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm
21. Sørensen HT, Christensen S, Mehnert F, et al: Use of bisphosphonates among women and risk of atrial fibrillation and flutter: Population based casecontrol study. BMJ 336:813-816, 2008 (Pubitemid 351548223)
22. Heckbert SR, Li G, Cummings SR, et al: Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 168:826-831, 2008 (Pubitemid 351649266)
23. Abrahamsen B, Eiken P, Brixen K: Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 265:581-592, 2009
24. Lewiecki EM, Cooper C, Thompson E, et al: Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Pract 64:821-826, 2010
25. Bunch TJ, Anderson JL, May HT, et al: Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 103:824-828, 2009
26. Grosso A, Douglas I, Hingorani A, et al: Oral bisphosphonates and risk of atrial fibrillation and flutter in women: A self-controlled case-series safety analysis. PLoS One 4:e4720, 2009
27. Loke YK, Jeevanantham V, Singh S: Bisphosphonates and atrial fibrillation: Systematic review and meta-analysis. Drug Saf 32:219-228, 2009
28. Kim SY, Kim MJ, Cadarette SM, et al: Bisphosphonates and risk of atrial fibrillation: A meta-analysis. Arthritis Res Ther 12:R30, 2010
29. Berenson JR, Lichtenstein A, Porter L, et al: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma: Myeloma Aredia Study Group. N Engl J Med 334:488-493, 1996 (Pubitemid 26067736)
30. Hortobagyi GN, Theriault RL, Porter L, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases: Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335:1785-1791, 1996 (Pubitemid 26412396)
31. Theriault RL, Lipton A, Hortobagyi GN, et al: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial - Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17:846-854, 1999 (Pubitemid 29109314)
32. Rosen LS, Gordon D, Kaminski M, et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7:377-387, 2001 (Pubitemid 33759002)
33. Saad F, Gleason DM, Murray R, et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468, 2002
34. Rosen LS, Gordon D, Tchekmedyian S, et al: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The Zoledronic Acid Lung Cancer and other Solid Tumors Study Group. J Clin Oncol 21:3150-3157, 2003 (Pubitemid 46606297)
35. Kohno N, Aogi K, Minami H, et al: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol 23:3314-3321, 2005
36. Arslan C, Aksoy S, Dizdar O, et al: Zoledronic acid and atrial fibrillation in cancer patients. Support Care Cancer [epub ahead of print on April 1, 2010]
37. Wilkinson GS, Baillargeon J, Kuo Y-F, et al: Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. J Clin Oncol 28:4898-4905, 2010
38. Giordano SH, Fang S, Duan Z, et al: Use of intravenous bisphosphonates in older women with breast cancer. Oncologist 13:494-502, 2008 (Pubitemid 351872867)